• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Oaktree Acquisition Corp II Cl A (NY: OACB )

    N/A UNCHANGED
    Last Price Updated: 7:00 PM EDT, Jun 15, 2022 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Oaktree Acquisition Corp II Cl A

    Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination
    From Alvotech Holdings S.A.
    Via Business Wire
    Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with Alvotech
    From Oaktree Acquisition Corp. II
    Via Business Wire
    Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®
    From Alvotech Holdings S.A.
    Via Business Wire
    Stocks That Hit 52-Week Lows On Thursday
    During the Thursday's session, 100 stocks hit new 52-week lows. 
    Via Benzinga
    Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®
    From Alvotech Holdings S.A.
    Via Business Wire
    Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination
    From Alvotech Holdings S.A.
    Via Business Wire
    Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange
    From Alvotech Holdings S.A.
    Via Business Wire
    Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie
    From Alvotech Holdings S.A.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2022
    Upgrades According to B. Riley Securities, the prior rating for BRT Apartments Corp (NYSE:BRT) was changed from Neutral to Buy. BRT Apartments earned $0.41 in the fourth quarter,... 
    Via Benzinga
    AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar
    Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-... 
    Via Benzinga
    Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million
    From Alvotech Holdings S.A.
    Via Business Wire
    Biosimilar Player Alvotech To Go Public Via $2.5B Oaktree SPAC Merger
    Biopharmaceutical company Alvotech Holdings SA plans to list on NASDAQ under the symbol ALVO by merging with a blank-check company backed by Oaktree Capital Management... 
    Via Benzinga
    Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company
    From Alvotech Holdings S.A.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.